Search the Newsreel

Revenue jumps to $31,927M at Anheuser-Busch InBev (NYSE: BUD)

Bausch + Lomb (BLCO) Stock Rallies On Margin Gains As Losses Narrow

AB InBev’s no-alcohol beer revenue rises 27% as beer volume grows

AB InBev reported solid second quarter 2026 results with revenue up 5.6% and underlying EPS increasing by 23.4%, driven by strong beer volume growth and strategic investments. The company saw significant growth in its no-alcohol beer portfolio, with revenue up 27%, and its megabrands …

Anheuser-Busch Inbev: Q2 Earnings Snapshot

AB InBev Reports Second Quarter 2026 Results

Figure 14. Terms and debt repayment schedule as of 30 June 2026 (billion USD) Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase BRUSSELS, July 30, 2026--(BUSINESS WIRE)--Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): …

Bausch Health Cos Q2 Earnings Call Highlights

Key Points Interested in Bausch Health Cos Inc.? Here are five stocks we like better. Bausch Health raised its full-year outlook after reporting strong second-quarter growth: excluding Bausch + Lomb, revenue rose 16% to $1.458 billion and adjusted EBITDA increased 28% to $865 million. …

Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Premium IOLs Help Propel Strong Q2 as Bausch + Lomb Reports Growth and Raises 2026 Guidance

Bausch + Lomb (NYSE/TSX: BLCO) reported strong second-quarter 2026 financial results, with total revenue increasing by 9 percent to $1.394 billion, driven by double-digit growth in surgical and pharmaceuticals. The company also raised its full-year 2026 revenue guidance. This growth was significantly propelled by …

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) reported $2.85 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.7%. EPS of $1.26 for the same period compares to $0.90 a year ago. The reported revenue represents a surprise of +7.62% over the Zacks …

Bausch & Lomb Earnings: Momentum in Implantables and Pharmaceuticals Shows Off Investment Dividends

Bausch & Lomb reported $1.4 billion in revenue, exceeding FactSet consensus by 2% and showing 9% year-over-year growth, though adjusted EPS of $0.17 was 3% below consensus. Despite the mixed earnings, shares remained flat. The report highlights strong first-half performance, indicating that the company's …

Bausch: Q2 Earnings Snapshot

Bausch + Lomb Upgrades Full-Year Outlook on Strong Second Quarter

Bausch + Lomb has upgraded its full-year outlook following a strong second quarter performance. This positive revision indicates the company's robust financial health and optimistic projections for the remainder of the year.

Bausch & Lomb Corp 2026: Revenue $1.39B, EPS ($0.04) — 10-Q Summary

Bausch & Lomb Corp (BLCO) reported strong second-quarter 2026 results with revenue reaching $1.39 billion, an increase driven by pricing and volume gains across segments. The company significantly reduced its net loss compared to the prior year, with diluted loss per share narrowing to …

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $258 million and GAAP Net Income of $260 million GAAP Earnings …

Bausch & Lomb Corp (BLCO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Bausch & Lomb Corp (NYSE:BLCO) reported 8% constant currency revenue growth, showcasing consistent performance across …

Bausch Health earnings up next as analysts eye profit surge

Bausch Health Companies Inc. is set to report second-quarter earnings, with analysts anticipating a significant profit surge. The company is expected to post earnings of $1.01 per share on revenue of $2.67 billion, driven by improving operating leverage and strategic initiatives like international expansion. …

AB INBEV : UBS reiterates its Buy rating

UBS has re-affirmed its Buy rating for AB InBev with a target price of EUR 88. This positive outlook from Sanjeet Aujla at UBS was published on July 29, 2026. The article highlights recent analyst activities for Anheuser-Busch InBev SA/NV, including other recent Buy …

Bausch + Lomb Corporation Raises Earnings Guidance for the Full Fiscal Year 2026

Bausch + Lomb Corporation has updated its earnings guidance for the full fiscal year 2026, raising its revenue expectations. The company now anticipates revenue to fall between $5.440 billion and $5.540 billion, an increase from its previous forecast of $5.420 billion to $5.520 billion.

Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was …

Earnings Flash (BLCO) Bausch + Lomb Corporation Posts Q2 Adjusted EPS $0.15 per Share, Vs. FactSet Est of $0.15

Bausch + Lomb Corporation (BLCO) announced its Q2 adjusted earnings per share (EPS) of $0.15, meeting FactSet's estimate. This financial report provides key insights into the company's performance for the second quarter.

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Revenue of $1.394 Billion Revenue Grew 9% as Reported and 8% on a Constant Currency1 Basis Compared to the Second Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14 Million Adjusted EBITDA (non-GAAP)1 of $241 Million; Adjusted EBITDA Excluding …

Sei Investments Co. Has $25.72 Million Position in Anheuser-Busch InBev SA/NV $BUD

Sei Investments Co. increased its stake in Anheuser-Busch InBev SA/NV by 24% in the first quarter, now holding 370,795 shares valued at $25.72 million. Several other hedge funds also adjusted their positions in the consumer goods maker. Anheuser-Busch InBev SA/NV (NYSE:BUD) stock is currently …

Anheuser-Busch InBev SA/NV (BUD) Earnings Date and Reports 2026 $BUD

Bausch + Lomb (NYSE: BLCO) lifts revenue but remains loss-making

Is Bausch + Lomb (BLCO) Undervalued As EyeGility Launch And Earnings Draw Focus?

Bausch + Lomb Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:BLCO) 2026-07-29

Bausch + Lomb (BLCO) reported strong Q2 2026 results, with an 8% constant currency revenue growth and a 28% increase in adjusted EBITDA, leading to a 17.6% adjusted EBITDA margin. The company raised its full-year revenue and adjusted EBITDA guidance, driven by consistent performance …

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 9.1% year on year to $1.39 billion. The company expects the full year's revenue to be around …

Bausch Health Rises After Q2 Earnings, Revenue Beat Estimates

Bausch + Lomb: Q2 Earnings Snapshot

Bausch + Lomb Corporation reported a Q2 loss of $14 million, or 4 cents per share, which adjusted to 16 cents per share, meeting Wall Street expectations. The company recorded revenue of $1.39 billion, exceeding analyst forecasts, and anticipates full-year revenue between $5.42 billion …

Bausch Health Companies Inc (BHC) Valuation: PE, PB & Fair Value Analysis

Bausch Health Companies Inc (BHC) has a current valuation score of 9.34, ranking 27th out of 155 companies in the Pharmaceuticals industry. The company's P/E ratio is -1.40, which is significantly below its recent high and above its recent low. However, relevant data for …

Bausch + Lomb Corp (BLCO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Bausch + Lomb Corp (BLCO), rating its current risk score at 7.06, placing it 43rd out of 199 in the Healthcare Equipment & Supplies industry. Key metrics include a beta of 0.58, indicating lower volatility compared to …

Bausch Health Companies Inc (BHC) Risk Assessment: Volatility, Financial Risk & Investment Risk

Bausch Health Companies Inc (BHC) has a current risk assessment score of 6.07, ranking 59 out of 155 in the Pharmaceuticals industry. The company's beta value of 0.42 indicates it may underperform during bull markets but experience smaller declines during bear markets. The report …

Stocks in play: Bausch Health Companies Inc.

Bausch Health Companies Inc. (T.BHC) announced that its PrELIDEL (pimecrolimus) cream is now approved for listing under Alberta's public drug plan for eligible patients. Following this announcement, the company's shares are trading up by $0.09 at $6.43.

Bausch Health Companies Inc.

Bausch Health Companies Inc. announced that its PrELIDEL® (pimecrolimus) cream has been listed under Alberta's public drug plan, making it available for eligible patients. Following this announcement, shares of Bausch Health Companies Inc. (T.BHC) saw an increase, trading up $0.09 at $6.43.

1 Reason to Buy NuScale Power Stock This August

NuScale Power (NYSE: SMR) remains one of the most popular nuclear energy stocks on the planet. And it's not hard to understand why. Bank of America analysts believe we're entering a nuclear renaissance driven by rising energy demand stemming from the global adoption of …

(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis

LAVAL, QC, July 28, 2026 /PRNewswire/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) announces that PrELIDEL® (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible patients. ELIDEL® cream is indicated for second-line therapy …